• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR
Mauna Kea Technologies Receives FDA Clearance and CE Marking For Its Next-Generation Cellvizio® Platform

Mauna Kea Technologies Receives FDA Clearance and CE Marking For Its Next-Generation Cellvizio® Platform

by Zina | Mar 3, 2020 | News

The new Cellvizio® platform includes significant improvements and will enable major innovations  Mauna Kea Technologies announced today that it has obtained 510(k) clearance (K193416) from the U.S. Food and Drug Administration (FDA) and CE marking of the...
Mauna Kea Technologies Receives FDA Clearance and CE Marking For Its Next-Generation Cellvizio® Platform

Mauna Kea Technologies reports fourth quarter and full year 2019 sales

by Zina | Jan 29, 2020 | News

 Full Year 2019 total sales up 10%  Sales to clinical customers up 27%, driven by 89% growth in consumables sales related to pay-per-use program  Fourth Quarter total sales down 20%  Fourth quarter sales to clinical customers down 18%, driven by...
Mauna Kea Technologies Receives FDA Clearance and CE Marking For Its Next-Generation Cellvizio® Platform

Mauna Kea Technologies Receives FDA 510(k) Clearance of Cellvizio® with a Fluorescent Dye, Fluorescein, as Drug Device Combination

by Zina | Jan 27, 2020 | News

The Cellvizio® 100 series system with all its different Confocal Miniprobes™ is now cleared for use with the fluorescein dye to image blood flow in the microvasculature and capillaries  Mauna Kea Technologies today announced that it has received...

UCI Gastroenterology & Hepatology Symposium, Anaheim, CA

by Zina | Jan 17, 2020 | Events

The 12th annual Gastroenterology & Hepatology Symposium will be held in Anaheim, CA, 28th-29th February 2020. Look at the program here Come join us at our booth !
Positive Results on Needle-Based Endomicroscopy for the Clinical Management of Pancreatic Cystic Lesions

Positive Results on Needle-Based Endomicroscopy for the Clinical Management of Pancreatic Cystic Lesions

by Zina | Jan 8, 2020 | News

Clinical trial published in peer-reviewed journal demonstrates diagnostic yield from Cellvizio® significantly exceeds standard of care (84.1% vs 34.1%); use of Cellvizio drives overall change in clinical management – including need for continued surveillance...
« Older Entries
Next Entries »

Articles récents

  • Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week® 2025 
  • Publication of the 2024 Annual Financial Report 
  • Digestive Disease Week 2025
  • Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio® in Key Indications 
  • Mauna Kea Technologies Reports Full Year 2024 Results and Provides a Business Update 

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}